Participants
HD, Damas, melanoma
BCC, MELANOMA
Full details and efficacy results of the intervention trial have been published (Lacson et al., 2022). Briefly, we recruited participants from eight primary care clinics in Tampa, FL (hereafter referred to as Tampeños), and Ponce, Juana Díaz, and Salinas, PR (Puerto Ricans) between September 2018 and January 2020. Participants were self-identified Hispanics at least 18 years old in Tampa and at least 21 years old in Puerto Rico, which are the respective ages of majority. We excluded individuals who had a skin examination within the past year, a previous diagnosis of melanoma, and more than one previous diagnosis of BCC and/or SCC.All participants gave written informed consent. The study was conducted based on the Declaration of Helsinki and was approved by the Institutional Review Boards of the University of South Florida (Tampa, FL; Pro00020044, approved August 30, 2018), Ponce Health Sciences University (Ponce, PR; 170,807-BS, approved December 6, 2017) and the Comité de Seguimiento de la Investigación Clínica at Hospital Damas (HD 19 − 17, approved December 18, 2017).